“
TL;DR
It concludes that novel approaches such as stem cell therapy, gene therapy, and protein-targeted degradation technologies show promise but remain largely preclinical, with significant hurdles to human translation.
International Journal of Molecular Sciences · 9 authors, 7 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
It concludes that novel approaches such as stem cell therapy, gene therapy, and protein-targeted degradation technologies show promise but remain largely preclinical, with significant hurdles to human translation.
Limited epidemiological data indicate that FTD occurs in approximately 11 cases per 100,000 individuals. The review notes that serotonergic modulators including trazodone and citalopram have shown modest behavioral benefit in FTD. Regarding emerging therapies, the authors report that much current stem cell therapy research is rooted in animal studies, creating a knowledge void regarding long-term human outcomes. Gene therapy delivery to the CNS via vectors such as AAV9 is described as safe in preliminary studies, though production costs and delivery challenges remain.